Working… Menu

Confirmatory Clinical Study of Oxiplex

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03433391
Recruitment Status : Completed
First Posted : February 14, 2018
Last Update Posted : July 2, 2020
Information provided by (Responsible Party):

Brief Summary:
This is a prospective, multi-center, randomized, controlled, patient and evaluator-blinded clinical study to assess the safety and effectiveness for the reduction of pain and symptoms following lumbar surgery.

Condition or disease Intervention/treatment Phase
Herniated Lumbar Disk Device: Oxiplex Other: Surgery Only Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 135 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Confirmatory Clinical Study to Support the Effectiveness and Safety of Oxiplex for the Reduction of Pain and Symptoms Following Lumbar Surgery
Actual Study Start Date : April 23, 2018
Actual Primary Completion Date : June 23, 2020
Actual Study Completion Date : June 23, 2020

Arm Intervention/treatment
Surgery Plus Oxiplex
Oxiplex will be applied after hemostasis is achieved and prior to closure, in adult patients undergoing single level partial discectomy.
Device: Oxiplex
Oxiplex is a clear, viscoelastic gel that is applied to operative site during lumbar spine surgery in order to coat the nerve root with a protective barrier.

Surgery Only
Standard of care procedures for adult patients undergoing single level partial discectomy will be followed.
Other: Surgery Only
Single level partial discectomy as per standard of care procedures.

Primary Outcome Measures :
  1. Change in ipsilateral leg pain [ Time Frame: Pre-op; 6 weeks; 3 months; 6 months ]
    Subjects will complete a Visual Analogue Scale (VAS) for their ipsilateral leg pain at each visit. The VAS is a continuous and linear, scale ranging from "No Pain" to "Worst Possible Pain".

Secondary Outcome Measures :
  1. Change in back pain [ Time Frame: Pre-op; 6 weeks; 3 months; 6 months ]
    Subjects will complete a Visual Analogue Scale (VAS) for their back pain at each visit.The VAS is a continuous and linear, scale ranging from "No Pain" to "Worst Possible Pain".

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   22 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Be between 22 and 70 years of age;
  2. Have symptomatic posterior or posterolateral disc herniation at L4-L5 or L5-S1 with radiographic confirmation of nerve compression using MRI that requires partial surgical discectomy with or without laminotomy;
  3. Have radiculopathy (e.g., decreased motor strength, sensory deficits, decreased reflexes) from specific nerve root distribution from L4 to S1 with positive straight leg raise (0-60 degrees);
  4. Have at least one of the following:

    1. At least six weeks of prior conservative treatment (e.g., physical therapy and/or use of anti-inflammatory medications, narcotics, and muscle relaxants at the manufacturer's recommended therapeutic dose);
    2. The patient is experiencing intractable pain; or
    3. There is substantial progression of loss of neurological function.
  5. Have VAS leg pain score in the ipsilateral leg of at least 60mm on a 100mm scale;
  6. Have VAS back pain score of at least 50mm on a 100mm scale;
  7. Be appropriate for treatment using a posterior surgical approach;
  8. Be likely to return for all follow-up visits; and
  9. Be willing and able to provide Informed Consent for study participation.

Exclusion Criteria:

Pre-Operative Exclusion Criteria:

  1. Radiographic confirmation (via MRI) of severe facet disease or facet degeneration at the index lumbar level;
  2. Prior spine surgery at any lumbar level;
  3. Subject requires spinal surgery other than a partial discectomy (with or without laminotomy) to treat leg/back pain (osteophyte removal is allowed);
  4. Previous trauma to the lumbar spine resulting in fracture or documented ligament injury;
  5. Documented presence of a free nuclear fragment at lumbar levels other than the study level;
  6. Axial back pain only (no radicular symptoms);
  7. Recent history (within previous six months) of chemical or alcohol dependence;
  8. Active systemic infection;
  9. Infection at the site of surgery;
  10. Cauda equina syndrome or neurogenic bowel/bladder dysfunction;
  11. Any terminal, systemic or autoimmune disease;
  12. Metabolic bone disease (e.g., osteoporosis/osteopenia, gout, osteomalacia, Paget's disease); as defined by use of anti-resorptive medications or a history of fragility fracture;
  13. Any disease, condition or surgery which might impair healing, such as:

    • Diabetes mellitus requiring daily insulin management,
    • Active malignancy,
    • History of metastatic malignancy;
  14. Treatment with any epidural steroids within four (4) weeks prior to the surgery;
  15. Treatment with any oral steroids within ten (10) days prior to the surgery;
  16. Treatment with aspirin or other non-steroidal anti-inflammatory drugs within seventy-two (72) hours prior to the surgery;
  17. Currently experiencing an episode of major mental illness (psychosis, major affective disorder, or schizophrenia), or manifesting physical symptoms without a diagnosable medical condition to account for the symptoms, which may indicate symptoms of psychological rather than physical origin;
  18. Pregnancy at time of enrollment, or planning to become pregnant, since this would contraindicate surgery2;
  19. Currently a prisoner;
  20. Currently involved in litigation which may influence the subject's reporting of symptoms including workers comp;
  21. Participation in any other investigational drug, biologic or medical device study within the last six months prior to study surgery;
  22. Requires removal of far lateral disc herniations at L4/5 or L5/S1.

Intra-operative Exclusion Criteria:

In case the surgeon identifies during surgery any circumstance that contradicts to the patient's participation in the trial, the surgeon should exclude the patient from trial participation. Exclusion reasons are:

  1. Severe facet disease or facet degeneration at the index lumbar level;
  2. Dural entry during surgery;
  3. Discovery of intraspinal tumor during surgery;
  4. Requires spinal fusion;
  5. Multilevel herniation or the need to involve more than one level;
  6. Exploration of contralateral side;
  7. Epidural fat placement;
  8. Application of products to the exposed neural element, including:

    • Amniotic tissue or fluids
    • Adhesives
    • Steroids
    • Platelet rich plasma
    • Gelfoam
    • Allograft tissue
    • Fibrin glue
    • Dural patches
  9. Surgical determination that a hemostatic agent must remain at the surgery site;
  10. Surgical determination of the need for any other device (that would interfere with interpretation of the study results) to remain at the surgery site (e.g., surgical drains);
  11. Adverse events or complications assessed during surgery that rule out the use of Oxiplex (e.g., infection, local osteoporosis);
  12. Application of a sealant or other attempt to repair annular tear;
  13. Implantation of antibiotic powder into the surgical wound. (Antibiotic irrigation may be used in the treatment group prior to Oxiplex application and the control group following surgery. No irrigation is allowed after Oxiplex application.);
  14. The presence of a dural tear and/or opening found during the surgical procedure.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03433391

Show Show 17 study locations
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Jeffrey Fischgrund, MD Beaumont Health
Additional Information:
Layout table for additonal information
Responsible Party: FzioMed Identifier: NCT03433391    
Other Study ID Numbers: FZ-SP007
First Posted: February 14, 2018    Key Record Dates
Last Update Posted: July 2, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes